Red cell aplasia: Acquired and congenital disorders

Wintrobe's Clinical Hematology: Thirteenth Edition

Volumn , Issue , 2013, Pages 975-989

  Lipton, Jeffrey M ^a,b   Glader, Bertil ^c,e   Means, Robert T ^d  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^b Steven and Alexandra Cohen Children's Medical Center of New York   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

^e LUCILE PACKARD CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84976570340     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (425)

1. Dessypris EN. Pure red cell aplasia. Baltimore, MD: Johns Hopkins University Press, 1988:1-156.
2. Freedman MH, Amato D, Saunders EF. Erythroid colony growth in congenital hypoplastic anemia. J Clin Invest 1976;57(3):673-677.
3. Krantz SB. Pure red-cell aplasia. N Engl J Med 1974;291(7):345-350.
4. Kaznelson P, Zur entstehung der blutplättchen. Verh Dtsch Ges Inn Med 1922;34:557-558.
5. Bhargava R, Dolai TK, Singhal D, et al. Pure red cell aplasia associated with thymoma: is thymectomy the cure? Leuk Res 2009;33(3):e17-e18.
6. Fujiu K, Kanno R, Shio Y, et al. Triad of thymoma, myasthenia gravis and pure red cell aplasia combined with Sjogren's syndrome. Jpn J Thorac Cardiovasc Surg 2004;52(7):345-348.
7. Jain D, Varma N, Vaiphei K, et al. Pure red cell aplasia with malignant thymoma: a rarity. Indian J Pathol Microbiol 2006;49(4):553-554.
8. Chikkappa G, Zarrabi MH, Tsuan MF. Pure red cell aplasia in patients with chronic lymphocytic leukemia. Medicine (Baltimore) 1986;65:339-351.
9. Tanna S, Ustun C. Immunosuppressive treatment in patient with pure red cell aplasia associated with chronic myelomonocytic leukemia: harm or benefit? Int J Hematol 2009;90(5):597-600.
10. D'Arena G, Cascavilla N. Chronic lymphocytic leukemia-associated pure red cell aplasia. Int J Immunopathol Pharmacol 2009;22(2):279-286.
11. Hoffman R, Kopel S, Hsu SD, et al. T cell chronic lymphocytic leukemia: presence in bone marrow and peripheral blood of cells that suppress erythropoiesis in vitro. Blood 1978;52(1):255-260.
12. Morgan E, Pang KM, Goldwasser E. Hodgkin disease and red cell aplasia. Am J Hematol 1978;5(1):71-75.
13. Vlachaki E, Diamantidis MD, Klonizakis P, et al. Pure red cell aplasia and lymphoproliferative disorders: an infrequent association. SciWorld J 2012;2012:475313.
14. Hirokawa M, Sawada K, Fujishima N, et al. Acquired pure red cell aplasia associated with malignant lymphomas: a nationwide cohort study in Japan for the PRCA Collaborative Study Group. Am J Hematol 2009;84(3):144-148.
15. Anastasiadis A, Margaritis D, Kotsianidis I, et al. Pure red cell aplasia as first manifestation of splenic marginal zone lymphoma-successful treatment with rituximab: a case report. Cases J 2009;2:6913.
16. Tsujimura H, Sakai C, Takagi T. Pure red cell aplasia complicated by angioimmunoblastic T-cell lymphoma: humoral factor plays a main role in the inhibition of erythropoiesis from CD34(+) progenitor cells. Am J Hematol 1999;62(4):259-260.
17. Al Hilali M, Joyner MV. Pure red-cell aplasia secondary to angioimmunoblastic lymphadenopathy. J R Soc Med 1983;76(10):894-895.
18. Alberti E, Aldovini D, Mazzon C, et al. Angioimmunoblastic lymphadenopathy with dysproteinemia. Report of a case with pure red cell aplasia. Haematologica 1982;67(6):919-925.
19. Choi JH, Oh YH, Park IK. A case of pure red cell aplasia associated with angioimmunoblastic T-cell lymphoma. Cancer Res Treat 2010;42(2):115-117.
20. Lynch JW, Elfenbein GJ, Noyes WD, et al. Pure red cell aplasia associated with angioimmunoblastic lymphadenopathy with dysproteinemia. Am J Hematol 1994;46(2):72-78.
21. Orchard J, Myint H, Hamblin TJ. A patient with myeloma who still has pure red cell aplasia despite the most intensive immune modulation. Leuk Res 1997;21(4):353-354.
22. Gilbert EF, Harley JB, Anido V, et al. Thymoma, plasma cell myeloma, red cell aplasia and malabsorption syndrome. Am J Med 1968;44(5):820-829.
23. Masauzi N, Tanaka J, Watanabe M, et al. Primary Waldenstrom's macroglobulinemia associated with pure red cell aplasia in which Ts/c lymphocytes inhibiting erythroid precursors were detected. Rinsho Ketsueki 1993;34(3):355-361.
24. Dessypris EN, McKee CL Jr, Metzantonakis C, et al. Red cell aplasia and chronic granulocytic leukaemia. Br J Haematol 1981;48(2):217-225.
25. Hirri HM, Green PJ. Pure red cell aplasia in a patient with chronic granulocytic leukaemia treated with interferon-alpha. Clin Lab Haematol 2000;22(1):53-54.
26. Barosi G, Baraldi A, Cazzola M, et al. Red cell aplasia in myelofibrosis with myeloid metaplasia. A distinct functional and clinical entity. Cancer 1983;52(7):1290-1296.
27. Howarth JE, Waters HM, Geary CG. Red cell aplasia in myelofibrosis. Br J Haematol 1989;72(1):114.
28. Sarode R, Bambery P, Marwaha N, et al. Pure red cell aplasia associated with essential thrombocythemia (a case report). Indian J Cancer 1990;27(3): 138-142.
29. Brafield AJ, Verbov J. A case of thrombocythaemia with red cell aplasia. Postgrad Med J 1966;42(490):525-526.
30. Zhang M, Hu S, Ashwani N, et al. Pediatric T-cell acute lymphoblastic leukemia with transient pure red cell aplasia. Pediatr Blood Cancer 2012;58(6): 1002-1003.
31. Nishioka R, Nakajima S, Morimoto Y, et al. T-cell acute lymphoblastic leukemia with transient pure red cell aplasia associated with myasthenia gravis and invasive thymoma. Intern Med 1995;34(2):127-130.
32. Imamura N, Kuramoto A, Morimoto T, et al. Pure red cell aplasia associated with acute lymphoblastic leukaemia of pre-T-cell origin. Med J Aust 1986;144(13):724.
33. Tanaka H, Iwato K, Asou H, et al. Pure red cell aplasia associated with imatinib-treated FIP1L1-PDGFRA positive chronic eosinophilic leukemia. Intern Med 2010;49(12):1195-200.
34. Gajwani B, Zinner EN. Pure red-cell aplasia. Associated with adenocarcinoma of stomach. N Y State J Med 1976;76(13):2177-2179.
35. Harris SJ, Seah JA, Barnett F, et al. Inflammatory breast cancer and secondary pure red cell aplasia. Acta Oncol 2011;50(5):727-728.
36. Lee CH, Clark AR, Thorpe ME, et al. Bile duct adenocarcinoma with Leser-Trelat sign and pure red blood cell aplasia. Cancer 1980;46(7):1657-1660.
37. Tauchi T, Iwama H, Kaku H, et al. Remission of pure-red-cell aplasia associated with operative cure of lung cancer. Am J Hematol 1999;61(2):157-158.
38. Gordon IO, Wade T, Chin K, et al. Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Cancer Immunol Immunother 2009;58(8):1351-1353.
39. Carneiro BA, Watkin WG, Mehta UK, et al. Metastatic basal cell carcinoma: complete response to chemotherapy and associated pure red cell aplasia. Cancer Invest 2006;24(4):396-400.
40. Iannucci A, Perini A, Pizzolo G. Acquired pure red cell aplasia associated with thyroid carcinoma: case report. Acta Haematol 1983;69(1):62-63.
41. Fong PH, Wee A, Chan HL, et al. Primary thymic carcinoma and its association with dermatomyositis and pure red cell aplasia. Int J Dermatol 1992;31(6): 426-428.
42. Maekawa K, Shibata J, Nakagawa S, et al. Pure red cell aplasia associated with renal cell carcinoma. Nihon Naika Gakkai Zasshi 1989;78(7): 1002-1003.
43. Ketata W, Fouzi S, Msaad S, et al. Thymoma associated with pure red cell aplasia and Kaposi's sarcoma. Rev Mal Respir 2009;26(1):78-82.
44. Shimm DS, Logue GL, Rohlfing MB, et al. Primary amyloidosis, pure red cell aplasia, and Kaposi's sarcoma in a single patient. Cancer 1979;44(4): 1501-1503.
45. Kurtzman G, Frickhofen N, Kimball J, et al. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immu- noglobulin therapy. N Engl J Med 1989;321(8):519-523.
46. Frickhofen N, Chen ZJ, Young NS, et al. Parvovirus B19 as a cause of acquired chronic pure red cell aplasia. Br J Haematol 1994;87(4):818-824.
47. Abkowitz JL, Brown KE, Wood RW, et al. Clinical relevance of parvovirus B19 as a cause of anemia in patients with human immunodeficiency virus infection. J Infect Dis 1997;176(1):269-273.
48. Kaneko H, Shimura K, Nishida K, et al. Pure red cell aplasia caused by parvovirus B19 in two patients without chronic hemolysis. J Infect Chemother 2011;17(2):268-271.
49. Young N. Hematologic and hematopoietic consequences of B19 parvovirus infection. Semin Hematol 1988;25:159-172.
50. Frickhofen N, Young NS. Persistent parvovirus B19 infections in humans. Microb Pathog 1989;7(5):319-327.
51. Gottlieb F, Deutsch J. Red cell aplasia responsive to immunoglobulin therapy as initial manifestation of human immunodeficiency virus infection. Am J Med 1992;92(3):331-333.
52. Hisano S, Morioka E, Murakami G, et al. Adult T-cell leukemia associated with pure red cell aplasia-like lesion. Rinsho Ketsueki 1990;31(11):1831-1835.
53. Purtilo DT, Zelkowitz L, Harada S, et al. Delayed onset of infectious mononucleosis associated with acquired agammaglobulinemia and red cell aplasia. Ann Intern Med 1984;101(2):180-186.
54. Bruyn GA, Schelfhout LJ. Transient syndrome of inappropriate antidiuretic hormone secretion in a patient with infectious mononucleosis and pure red cell aplasia. Neth J Med 1986;29(5):167-169.
55. Li C, Wang HF. Hepatitis E virus-related acute liver failure associated with pure red cell aplasia. Hepatobiliary Pancreat Dis Int 2011;10(5):557-558.
56. Aterini S, Fusco I, Amato M. Pure red-cell aplasia in a peritoneal dialysis patient with HCV-related cryoglobulinemia in the absence of neutralizing antierythropoietin antibodies. J Nephrol 2004;17(5):744-746.
57. Lee TH, Oh SJ, Hong S, et al. Pure red cell aplasia caused by acute hepatitis A. Chonnam Med J 2011;47(1):51-53.
58. Ohno Y, Itakura A, Sano M, et al. Pure red cell aplasia and acute hepatitis during pregnancy. Gynecol Obstet Invest 2002;53(2):112-113.
59. Yoon YK, Park DW, Sohn JW, et al. Corticosteroid treatment of pure red cell aplasia in a patient with hepatitis A. Acta Haematol 2012;128(1):60-63.
60. Kumar V, Gupta S, Singh S, et al. Pure red cell aplasia associated with cytomegalovirus infection. J Pediatr Hematol Oncol 2010;32(4):315-316.
61. Sinha AK, Agarwal A, Lakhey M, et al. Pure red cell aplasia-report of 11 cases from eastern Nepal. Indian J Pathol Microbiol 2003;46(3):405-408.
62. Ozkaynak MF, Ortega JA, Miller J. Concurrence of transient asplenia and pure red cell aplasia. Eur J Pediatr 1990;149(8):542-544.
63. Mewawalla P, Bauer F, Dasanu CA. Lemierre syndrome caused by group C streptococci and associated with red cell aplasia and immune thrombocytopenia. South Med J 2011;104(3):244-246.
64. Solano C, Gomez-Reino F, Fernandez-Ranada JM. Pure red cell aplasia in kala-azar. Acta Haematol 1984;72(3):205-207.
65. Figueiredo S, Pio D, Martins M, et al. Transient pure red blood cell aplasia as clinical presentation of congenital hemolytic anemia: a case report. Cases J 2009;2:6814.
66. Scaramucci L, Niscola P, Ales M, et al. Pure red cell aplasia associated with hemolytic anemia refractory to standard measures and resolved by rituximab in an elderly patient. Int J Hematol 2008;88(3):343-344.
67. Arcasoy MO, Chao NJ. T-cell-mediated pure red-cell aplasia in systemic lupus erythematosus: response to cyclosporin A and mycophenolate mofetil. Am J Hematol 2005;78(2):161-163.
68. Gupta RK, Ezeonyeji AN, Thomas AS, et al. A case of pure red cell aplasia and immune thrombocytopenia complicating systemic lupus erythematosus: response to rituximab and cyclophosphamide. Lupus 2011;20(14):1547-1550.
69. Chan AY, Li EK, Tam LS, et al. Successful treatment of pure red cell aplasia associated with systemic lupus erythematosus with oral danazol and steroid. Rheumatol Int 2005;25(5):388-390.
70. Iwadate H, Kobayashi H, Shio K, et al. A case of systemic lupus erythematosus complicated by pure red cell aplasia and idiopathic portal hypertension after thymectomy. Mod Rheumatol 2006;16(2):109-112.
71. Orbach H, Ben-Yehuda A, Ben-Yehuda D, et al. Successful treatment of pure red cell aplasia in systemic lupus erythematosus with erythropoietin. J Rheumatol 1995;22(11):2166-2169.
72. Banavali SD, Parikh PM, Charak BS, et al. Corticosteroid-responsive pure red cell aplasia in rheumatoid arthritis and its association with pregnancy: a case report. Am J Hematol 1989;31(1):58-61.
73. Julkunen H, Jantti J, Pettersson T. Pure red cell aplasia in mixed connective tissue disease. J Rheumatol 1989;16(10):1385-1386.
74. Myers TJ, Bower BF, Hild DH. Pure red cell aplasia and the syndrome of multiple endocrine gland insufficiency. Am J Med Sci 1980;280(1):29-34.
75. Meyer RJ, Hoffman R, Zanjani ED. Autoimmune hemolytic anemia and periodic pure red cell aplasia in systemic lupus erythematosus. Am J Med 1978;65(2):342-345.
76. Mangan KF, Besa EC, Shadduck RK, et al. Demonstration of two distinct antibodies in autoimmune hemolytic anemia with reticulocytopenia and red cell aplasia. Exp Hematol 1984;12(10):788-793.
77. Taniguchi S, Shibuya T, Morioka E, et al. Demonstration of three distinct immunological disorders on erythropoiesis in a patient with pure red cell aplasia and autoimmune haemolytic anaemia associated with thymoma. Br J Haematol 1988;68(4):473-477.
78. Fox RM, Firkin FC. Sequential pure red cell and megakaryocyte aplasia associated with chronic liver disease and ulcerative colitis. Am J Hematol 1978;4(1):79-85.
79. Trinchet JC, Lacombe C, Islam S, et al. Association of autoimmune chronic active hepatitis and acquired erythroblastopenia cured by cyclophosphamide. Gastroenterol Clin Biol 1986;10(12):841-844.
80. Kawano Y, Katayama Y, Okamura A, et al. Pure red cell aplasia with primary sclerosing cholangitis. Int J Hematol 2008;88(5):599-601.
81. Aggio MC, Zunini C. Reversible pure red-cell aplasia in pregnancy. N Engl J Med 1977;297(4):221-222.
82. Majer RV, Green PJ. Recurrent reversible pure red cell aplasia in pregnancy. Clin Lab Haematol 1988;10(1):101-103.
83. Bambery P, Varma N, Varma S, et al. Prolonged, pregnancy-related pure red cell aplasia; a case report. Eur J Obstet Gynecol Reprod Biol 1991;42(3):233-235.
84. Baker RI, Manoharan A, de Luca E, et al. Pure red cell aplasia of pregnancy: a distinct clinical entity. Br J Haematol 1993;85(3):619-622.
85. Miller AC, Rashid RM. Three episodes of acquired pure red cell aplasia restricted to pregnancy. J Perinat Med 2008;36(3):270-271.
86. Kashyap R, Pradhan M. Maternal and fetal outcome in pregnancy-associated pure red cell aplasia. J Obstet Gynaecol 2010;30(7):733-734.
87. Saeki A, Kaito K, Kobayashi M, et al. Pure red cell aplasia complicated with polyarthritis, angitis, and acute renal failure. Rinsho Ketsueki 1993;34(11):1480-1485.
88. Foy H, Kondi A, Macdougall L. Pure red-cell aplasia in marasmus and kwashiorkor treated with riboflavine. Br Med J 1961;1(5230):937-941.
89. Dan K, Ito T, Nomura T. Pure red cell aplasia following pernicious anemia. Am J Hematol 1990;33(2):148-150.
90. Alfrey CP, Lane M. The effect of riboflavin deficiency on erythropoiesis. Semin Hematol 1970;7(1):49-54.
91. Chanarin I. Investigation and management of megaloblastic anaemia. Clin Haematol 1976;5:747-763.
92. Agrawal A, Parrott NR, Riad HN, et al. Azathioprine-induced pure red cell aplasia: case report and review. Transplant Proc 2004;36(9):2689-2691.
93. Fujisawa S, Maruta A, Sakai R, et al. Pure red cell aplasia after major ABO-incompatible bone marrow transplantation: two case reports of treatment with recombinant human erythropoietin. Transpl Int 1996;9(5): 506-508.
94. Mueller RJ, Stussi G, Odermatt B, et al. Major ABO-incompatible hematopoietic stem cell transplantation: study of post-transplant pure red cell aplasia and endothelial cell chimerism. Xenotransplantation 2006;13(2):126-132.
95. Helbig G, Stella-Holowiecka B, Wojnar J, et al. Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies. Ann Hematol 2007;86(9):677-683.
96. Sora F, De Matteis S, Piccirillo N, et al. Rituximab for pure red cell aplasia after ABO-mismatched allogeneic peripheral blood progenitor cell transplantation. Transfusion 2005;45(4):643-645.
97. Funabiki K, Kaneko S, Terajima M, et al. A case of multicentric Castleman's disease associated with renal amyloidosis and pure red cell aplasia. Am J Nephrol 1998;18(3):247-250.
98. Hattori K, Irie S, Isobe Y, et al. Multicentric Castleman's disease associated with renal amyloidosis and pure red cell aplasia. Ann Hematol 1998;77(4):179-181.
99. Casadevall N, Nataf J, Viron B. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-475.
100. Macdougall IC. Epoetin-induced pure red cell aplasia: diagnosis and treatment. Curr Opin Nephrol Hypertens 2007;16(6):585-588.
101. Jepson JH, Lowenstein L. Inhibition of erythropoiesis by a factor present in the plasma of patients with erythroblastopenia. Blood 1966;27(4):425-434.
102. Zalusky R, Zanjani ED, Gidari AS, et al. Site of action of a serum inhibitor of erythropoiesis. J Lab Clin Med 1973;81(6):867-875.
103. Krantz SB, Kao V. Studies on red cell aplasia. II. Report of a second patient with an antibody to erythroblast nuclei and a remission after immunosuppressive therapy. Blood 1969;34(1):1-13.
104. Krantz SB, Kao V. Studies on red cell aplasia. I. Demonstration of a plasma inhibitor to heme synthesis and an antibody to erythroblast nuclei. Proc Natl Acad Sci U S A 1967;58(2):493-500.
105. Means RT, Dessypris EN, Krantz SB. Treatment of refractory pure red cell aplasia with cyclosporine A: in vitro correlation of clinical response. Br J Haematol 1991;78:114-119.
106. Lacombe C, Casadevall N, Muller O, et al. Erythroid progenitors in adult chronic pure red cell aplasia: relationship of in vitro erythroid colonies to therapeutic response. Blood 1984;64(1):71-77.
107. Katz LJ, Hoffman R, Ritchey AK, et al. The proliferative capacity of pure red cell aplasia bone marrow cells. Yale J Biol Med 1981;54(2):89-94.
108. Charles RJ, Sabo KM, Kidd PG, et al. The pathophysiology of pure red cell aplasia: implications for therapy. Blood 1996;87(11):4831-4838.
109. Dessypris EN, Krantz SB, Roloff JS, et al. Mode of action of the IgG inhibitor of erythropoiesis in transient erythroblastopenia of childhood. Blood 1982;59: 114-123.
110. Krantz SB, Moore WH, Zaentz SD. Studies on red cell aplasia. V. Presence of erythroblast cytotoxicity in G-globulin fraction of plasma. J Clin Invest 1973;52(2):324-336.
111. Zaentz SD, Luna JA, Baker AS, et al. Detection of cytotoxic antibody to erythroblasts. J Lab Clin Med 1977;89:851-860.
112. Peschle C, Marmont AM, Marone G, et al. Pure red cell aplasia: studies on an IgG serum inhibitor neutralizing erythropoietin. Br J Haematol 1975;30(4):411-417.
113. Jepson JH, Lowenstein L. Panhypoplasia of the bone marrow. I. Demonstration of a plasma factor with anti-erythropoietin-like activity. Can Med Assoc J 1968;99(3):99-101.
114. Hara T, Mizuno Y, Nagata M, et al. Human gamma delta T-cell receptor-positive cell-mediated inhibition of erythropoiesis in vitro in a patient with type I autoimmune polyglandular syndrome and pure red blood cell aplasia. Blood 1990;75(4):941-950.
115. Mangan KF. T-cell-mediated suppression of hematopoiesis. N Engl J Med 1985;312(5):306-307.
116. Mangan KF, Chikkappa G, Farley PC. T gamma (T gamma) cells suppress growth of erythroid colony-forming units in vitro in the pure red cell aplasia of B-cell chronic lymphocytic leukemia. J Clin Invest 1982;70(6):1148-1156.
117. Mangan KF, Chikkappa G, Scharfman WB, et al. Evidence for reduced erythroid burst (BFUE) promoting function of T lymphocytes in the pure red cell aplasia of chronic lymphocytic leukemia. Exp Hematol 1981;9(5): 489-498.
118. Masuda M, Arai Y, Okamura T, et al. Pure red cell aplasia with thymona: evidence of T-cell clonal disorder. Am J Hematol 1997;54(4):324-328.
119. Masuda M, Teramura M, Matsuda A, et al. Clonal T cells of pure red-cell aplasia. Am J Hematol 2005;79(4):332-333.
120. Soler J, Estivill X, Ayats R, et al. Chronic T-cell lymphocytosis associated with pure red call aplasia, thymoma and hypogammaglobulinemia. Br J Haematol 1985;61(3):582-584.
121. Abkowitz JL, Kadin ME, Powell JS, et al. Pure red cell aplasia: lymphocyte inhibition of erythropoiesis. Br J Haematol 1986;63(1):59-67.
122. Wranne L. Transient erythroblastopenia in infancy and childhood. Scand J Haematol 1970;7(2):76-81.
123. Glader BE. Transient erythroblastopenia of childhood. West J Med 1988;149(4):453-454.
124. Dessypris EN, Krantz SB, Roloff JS, et al. Mode of action of the IgG inhibitor of erythropoiesis in transient erythroblastopenia of children. Blood 1982;59(1): 114-123.
125. Koenig HM, Lightsey AL, Nelson DP, et al. Immune suppression of erythropoiesis in transient erythroblastopenia of childhood. Blood 1979;54(3):742-746.
126. Dessypris EN, Fogo A, Russell M, et al. Studies on pure red cell aplasia. X. Association with acute leukemia and significance of bone marrow karyotype abnormalities. Blood 1980;56(3):421-426.
127. Pattison JR, Jones SE, Hodgson J, et al. Parvovirus infections and hypoplastic crisis in sickle-cell anaemia. Lancet 1981;1(8221):664-665.
128. Anderson MJ, Davis LR, Hodgson J, et al. Occurrence of infection with a parvovirus-like agent in children with sickle cell anaemia during a two-year period. J Clin Pathol 1982;35(7):744-749.
129. Serjeant GR, Topley JM, Mason K, et al. Outbreak of aplastic crises in sickle cell anaemia associated with parvovirus-like agent. Lancet 1981;2(8247):595-597.
130. Duncan JR, Potter CB, Cappellini MD, et al. Aplastic crisis due to parvovirus infection in pyruvate kinase deficiency. Lancet 1983;2(8340):14-16.
131. Kelleher JF Jr, Luban NL, Cohen BJ, et al. Human serum parvovirus as the cause of aplastic crisis in sickle cell disease. Am J Dis Child 1984;138(4): 401-403.
132. Frickhofen N, Arnold R, Hertenstein B, et al. Parvovirus B19 infection and bone marrow transplantation. Ann Hematol 1992;64(Suppl):A121- A124.
133. Soutar RL, Birnie DH, Bennett B. Parvovirus B19 induced red cell aplasia in myelofibrosis. Br J Haematol 1993;85(3):623-624.
134. Plentz A, Hahn J, Holler E, et al. Long-term parvovirus B19 viraemia associated with pure red cell aplasia after allogeneic bone marrow transplantation. J Clin Virol 2004;31(1):16-19.
135. Hayes-Lattin B, Seipel TJ, Gatter K, et al. Pure red cell aplasia associated with parvovirus B19 infection occurring late after allogeneic bone marrow transplantation. Am J Hematol 2004;75(3):142-145.
136. Garewal G, Ahluwalia J, Varma N, et al. Parvovirus B19 infection-associated red-cell aplasia in renal-transplant recipients: clues from the bone marrow. Transplantation 2004;77(2):320-321.
137. Helbig G, Stella-Holowiecka B, Krawczyk-Kulis M, et al. Successful treatment of pure red cell aplasia with repeated, low doses of rituximab in two patients after ABO-incompatible allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia. Haematologica 2005;90(Suppl): ECR33.
138. Vales-Albertos LJ, Garcia-Cardenas M, Chavez-Becerra S, et al. Pure red cell aplasia associated with parvovirus B19 infection in renal transplantation: the first case report in Mexico. Transplantation 2005;79(6):739.
139. Pitchaipillai S, Kelsey P, Haeney M. Persistent pure red cell aplasia due to parvovirus B19 infection in a patient with Turner's syndrome. Clin Lab Haematol 2006;28(5):347-350.
140. Intalapaporn P, Poovorawan Y, Suankratay C. Immune reconstitution syndrome associated with parvovirus B19-induced pure red cell aplasia during highly active antiretroviral therapy. J Infect 2006;53(2):e79-e82.
141. Poplar S, Allford S, Rooney N. Chronic parvovirus B19 infection leading to red cell aplasia following treatment of Hodgkin lymphoma. Br J Haematol 2010;148(5):671.
142. Young N, Harrison M, Moore J, et al. Direct demonstration of the human parvovirus in erythroid progenitor cells infected in vitro. J Clin Invest 1984;74(6):2024-2032.
143. Brown KE, Anderson SM, Young NS, Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 1993;262(5130):114-117.
144. Brown KE, Hibbs JR, Gallinella G, et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med 1994;330(17):1192-1196.
145. Yaegashi N, Niinuma T, Chisaka H, et al. Parvovirus B19 infection induces apoptosis of erythroid cells in vitro and in vivo. J Infect 1999;39(1):68-76.
146. Morita E, Nakashima A, Asao H, et al. Human parvovirus B19 nonstructural protein (NS1) induces cell cycle arrest at G(1) phase. J Virol 2003;77(5): 2915-2921.
147. Sol N, Le Junter J, Vassias I, et al. Possible interactions between the NS-1 protein and tumor necrosis factor alpha pathways in erythroid cell apoptosis induced by human parvovirus B19. J Virol 1999;73(10):8762-8770.
148. Pillet S, Le GN, Hofer T, et al. Hypoxia enhances human B19 erythrovirus gene expression in primary erythroid cells. Virology 2004;327(1):1-7.
149. Casadevall N, Dupuy E, Molho-Sabatier P, et al. Brief report: autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med 1996;334(10):630-633.
150. Prabhakar SS, Muhlfelder T. Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin Nephrol 1997;47(5):331-335.
151. Gershon SK, Luksenburg H, Cote TR, et al. Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med 2002;346(20):1584-1586.
152. Nigg L, Schanz U, Ambuhl PM, et al. Prolonged course of pure red cell aplasia after erythropoietin therapy. Eur J Haematol 2004;73(5):376-379.
153. Panchapakesan U, Austin SK, Shafransky A, et al. Recovery of pure red-cell aplasia secondary to antierythropoietin antibodies after cessation of recombinant human erythropoietin. Intern Med J 2003;33(9-10):468-471.
154. Quint L, Casadevall N, Giraudier S, Pure red cell aplasia in patients with refractory anaemia treated with two different recombinant erythropoietins. Br J Haematol 2004;124(6):842.
155. Snanoudj R, Beaudreuil S, Arzouk N, et al. Recovery from pure red cell aplasia caused by anti-erythropoietin antibodies after kidney transplantation. Am J Transplant 2004;4(2):274-277.
156. Vergeist D, Rossert J, Casadevall N, et al. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet 2004;363:1768-1771.
157. Boven K, Knight J, Bader F, et al. Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. Nephrol Dial Transplant 2005;20(Suppl 3):iii33- iii40.
158. Bennett CL, Cournoyer D, Carson KR, et al. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood 2005;106(10):3343-3347.
159. Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004;351(14):1403-1408.
160. Berliner N. Rose MG. The incidence and characteristics of recombinant erythropoietin-associated pure red-cell aplasia. Curr Hematol Rep 2005;4(2):93-94.
161. Casadevall N, Cournoyer D, Marsh J, et al. Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia. Eur J Haematol 2004;73(6):389-396.
162. Collins AJ, Li S, Adamson JW, et al. Assessment of pure red cell aplasia in US dialysis patients: the limits of the Medicare data. Am J Kidney Dis 2004;43(3):464-470.
163. D'Arena G, Vigliotti ML, Dell'Olio M, et al. Rituximab to treat chronic lymphoproliferative disorder-associated pure red cell aplasia. Eur J Haematol 2009;82(3):235-239.
164. Evens AM, Bennett CL, Luminari S. Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the Research on Adverse Drug Events and Reports (RADAR) group. Best Pract Res Clin Haematol 2005;18(3):481-489.
165. Macdougall IC. Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another. Curr Med Res Opin 2004;20(1):83-86.
166. Boven K, Stryker S, Knight J, et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 2005;67(6):2346-2353.
167. Locatelli F, Aljama P, Barany P, et al. Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: where are we now and where do we go from here? Nephrol Dial Transplant 2004;19(2):288-293.
168. Schellekens H. Immunologic mechanisms of EPO-associated pure red cell plasia. Best Pract Res Clin Haematol 2005;18(3):473-480.
169. Schellekens H. Erythropoietic proteins and antibody-mediated pure red cell aplasia: a potential role for micelles. Nephrol Dial Transplant 2004;19(9):2422.
170. Schellekens H, Jiskoot W. Eprex-associated pure red cell aplasia and leachates. at Biotechnol 2006;24(6):613-614.
171. Delluc S, Ravot G, Maillere B. Quantification of the preexisting CD4 T-cell repertoire specific for human erythropoietin reveals its immunogenicity otential. Blood 2010;116(22):4542-4545.
172. Macdougall IC. Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks. Nephrol Dial Transplant 2005;20(Suppl 4):iv9- iv15.
173. Praditpornsilpa K, Kupatawintu P, Mongkonsritagoon W, et al. The association of anti-r-HuEpo-associated pure red cell aplasia with HLA-DRB1*09DQB1*0309. Nephrol Dial Transplant 2009;24(5):1545-1549.
174. Praditpornsilpa K, Tiranathanagul K, Kupatawintu P, et al. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int 2011;80(1):88-92.
175. al-Mondhiry H, Zanjani ED, Spivack M, et al. Pure red cell aplasia and thymoma: loss of serum inhibitor of erythropoiesis following thymectomy. Blood 1971;38(5):576-582.
176. Hirst E, Roberstson TI. The syndrome of thymoma and erythroblastopenic anemia: a review of 56 cases including 3 cases reports. Medicine (Baltimore) 1967;46:225.
177. Parry EH, Kilpatrick GS, Hardisty RM. Red-cell aplasia and benign thymoma; studies on a case responding to prednisone. Br Med J 1959;1(5130): 1154-1156.
178. Hirokawa M, Sawada K, Fujishima N, et al. Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia: a nationwide cohort study in Japan by the PRCA collaborative study group. Haematologica 2008;93(1):27-33.
179. Thompson CA. Pure red cell aplasia and thymoma. J Thorac Oncol 2007;2(4):263-264.
180. Srinivas U, Mahapatra M, Saxena R, et al. Thirty-nine cases of pure red cell aplasia: a single center experience from India. Hematology 2007;12(3): 245-248.
181. Mangan KF, Volkin R, Winkelstein A. Autoreactive erythroid progenitor-T suppressor cells in the pure red cell aplasia associated with thymoma and panhypogammaglobulinemia. Am J Hematol 1986;23(2):167-173.
182. Fujishima N, Hirokawa M, Fujishima M, et al. Oligoclonal T cell expansion in blood but not in the thymus from a patient with thymoma-associated pure red cell aplasia. Haematologica 2006;91(12 Suppl):ECR47.
183. Fujishima N, Sawada K, Hirokawa M, et al. Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-associated pure red cell aplasia: a Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group. Haematologica 2008;93(10):1555-1559.
184. Lipton JM, Nadler LM, Canellos GP, et al. Evidence for genetic restriction in the suppression of erythropoiesis by a unique subset of T lymphocytes in man. J Clin Invest 1983;72(2):694-706.
185. Nagasawa T, Abe T, Nakagawa T. Pure red cell aplasia and hypogammaglobulinemia associated with Tr-cell chronic lymphocytic leukemia. Blood 1981;57(6):1025-1031.
186. Handgretinger R, Geiselhart A, Moris A, et al. Pure red-cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-cell inhibitory receptors. N Engl J Med 1999;340(4):278-284.
187. Casado LF, Granados E, Algara P, et al. High expression of the ILT2 (LIR-1) inhibitory receptor for major histocompatibility complex class I molecules on clonal expansions of T large granular lymphocytes in asymptomatic patients. Haematologica 2001;86(5):457-463.
188. Nitta H, Mihara K, Sakai A, et al. Expansion of CD8+ /perforin+ effector memory T cells in the bone marrow of patients with thymoma-associated pure red cell aplasia. Br J Haematol 2010;150(6):712-715.
189. Assimakopoulos SF, Michalopoulou S, Melachrinou M, et al. Primary Sjögren syndrome complicated by autoimmune hemolytic anemia and pure red cell aplasia. Am J Med Sci 2007;334(6):493-496.
190. Franzen P, Friman C, Pettersson T, et al. Combined pure red cell aplasia and primary autoimmune hypothyroidism in systemic lupus erythematosus. Arthritis Rheum 1987;30(7):839-840.
191. Francis DA. Pure red-cell aplasia: association with systemic lupus erythematosus and primary autoimmune hypothyroidism. Br Med J (Clin Res Ed) 1982;284(6309):85.
192. Balasubramanian S, Kaarthigeyan K, Rajkumar J, et al. Pyoderma gangrenosum with pure red cell aplasia. Indian Pediatr 2010;47(6):529-531.
193. Dessypris EN, Baer MR, Sergent JS, et al. Rheumatoid arthritis and pure red cell aplasia. Ann Intern Med 1984;100(2):202-206.
194. Cavalcant J, Shadduck RK, Winkelstein A, et al. Red-cell hypoplasia and increased bone marrow reticulin in systemic lupus erythematosus: reversal with corticosteroid therapy. Am J Hematol 1978;5(3):253-263.
195. Fang B, Song Y, Zhao RC, et al. Treatment of resistant pure red cell aplasia after major ABO-incompatible bone marrow transplantation with human adipose tissue-derived mesenchymal stem cells. Am J Hematol 2007;82(8):772-773.
196. Tsai HJ, Lin SF, Liu TC, et al. Pure red cell aplasia after ABO major-mismatched allogeneic peripheral blood stem cell transplantation successfully treated with plasma exchange and low-dose steroid: two case reports. Kaohsiung J Med Sci 2004;20(3):128-132.
197. Zhu KE, Li JP, Zhang T, et al. Clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation. Hematology 2007;12(2):117-121.
198. Lagadinou ED, Marangos M, Liga M, et al. Human herpesvirus 6-related pure red cell aplasia, secondary graft failure, and clinical severe immune suppression after allogeneic hematopoietic cell transplantation successfully treated with foscarnet. Transpl Infect Dis 2010;12(5):437-440.
199. Koiso H, Kobayashi S, Ueki K, et al. Pure red cell aplasia accompanied by autoimmune hemolytic anemia in a patient with type A viral hepatitis. Rinsho Ketsueki 2009;50(5):424-429.
200. Sung HJ, Kim SJ, Lee JH, et al. Persistent anemia in a patient with diffuse large B cell lymphoma: pure red cell aplasia associated with latent Epstein-Barr virus infection in bone marrow. J Korean Med Sci 2007;22(Suppl):S167- S170.
201. MacCullough D, Jackson JM, Venerys J. Drug-induced red cell aplasia. Br Med J 1974;4:163.
202. Gollan JL, Hussein S, Hoffbrand AV, et al. Red cell aplasia following prolonged d-penicillamine therapy. J Clin Pathol 1976;29:135.
203. Dunn AM, Kerr GD. Pure red cell aplasia associated with sulfasalazine. Lancet 1981;2:1288.
204. Nicholls MD, Concannon AJ. Maloprim-induced agranulocytosis and red cell aplasia. Med J Aust 1982;2:564.
205. Claiborne RA, Dutt AK. Isoniazid-induced pure red cell aplasia. Am Rev of Respir Dis 1985;131:947.
206. Dessypris EN, Redline S, Harris JW, et al. Diphenylhydantoin-induced pure red cell aplasia. Blood 1985;65:789.
207. Tsuda H, Kuniyasu W, Fukuda K, et al. Pure red cell aplasia caused by chlormadinone. Lancet 1994;344(8933):1370-1371.
208. Arcasoy MO, Rockey DC, Heneghan MA. Pure red cell aplasia following pegylated interferon alpha treatment. Am J Med 2004;117(8):619-620.
209. The T, Kolla R, Dawkins F, et al. Pure red cell aplasia after 13 years of sodium valproate, and bone marrow suppression after 17 years of carbamazepine. PLoS Med 2004;1(2):e51.
210. Yamamoto N, Shiraki K, Saitou Y, et al. Ticlopidine induced acute cholestatic hepatitis complicated with pure red cell aplasia. J Clin Gastroenterol 2004;38(1):84.
211. Borras-Blasco J, Conesa-Garcia V, Navarro-Ruiz A, et al. Pure red cell aplasia associated with dapsone therapy. Ann Pharmacother 2005;39(6):1137-1138.
212. Chao SC, Yang CC, Lee JY. Hypersensitivity syndrome and pure red cell aplasia following allopurinol therapy in a patient with chronic kidney disease. Ann Pharmacother 2005;39(9):1552-1556.
213. Weinkove R, Rangarajan S, van der Walt J, et al. Zidovudine-induced pure red cell aplasia presenting after 4 years of therapy. AIDS 2005;19(17):2046-2047.
214. Hodo Y, Tsuji K, Mizukoshi E, et al. Pure red cell aplasia associated with concomitant use of mycophenolate mofetil and ribavirin in post-transplant recurrent hepatitis C. Transpl Int 2006;19(2):170-171.
215. Pasha SF, Pruthi RK. Procainamide-induced pure red cell aplasia. Int J Cardiol 2006;110(1):125-126.
216. Elimelakh M, Dayton V, Park KS, et al. Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients. Haematologica 2007;92(8):1029-1036.
217. Bartakke S, Abdelhaleem M, Carcao M. Valproate-induced pure red cell aplasia and megakaryocyte dysplasia. Br J Haematol 2008;141(2):133.
218. John MA, Rhemtula YA, Menezes CN, et al. Lamivudine-induced red cell aplasia. J Med Microbiol 2008;57(Pt 8):1032-1035.
219. Hassan A, Babadoko AA, Mamman AI, et al. Zidovudine induced pure red cell aplasia: a case report. Niger J Med 2009;18(3):332-333.
220. Balakrishnan A, Valsalan R, Sheshadri S, et al. Zidovudine-induced reversible pure red cell aplasia. Indian J Pharmacol 2010;42(3):189-191.
221. Nakamura H, Okada A, Kawakami A, et al. Isoniazid-triggered pure red cell aplasia in systemic lupus erythematosus complicated with myasthenia gravis. Rheumatol Int 2010;30(12):1643-1645.
222. Chang CS, Yan SL, Lin HY, et al. Pure red cell aplasia caused by pegylated interferon-alpha-2a plus ribavirin in the treatment of chronic hepatitis C. World J Gastroenterol 2011;17(16):2155-2158.
223. Bennett CL, Starko KM, Thomsen HS, et al. Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye's syndrome. A report from the Southern Network on Adverse Reactions (SONAR). J Gen Intern Med 2012;27:1687-1703.
224. Waki F, Ohnishi H, Shintani T, et al. Linezolid-induced pure red cell aplasia in a patient with Staphylococcus epidermidis infection after allogeneic stem cell transplantation. Transpl Infect Dis 2012.
225. Reid G, Patterson AC. Pure red-cell aplasia after gold treatment. Br Med J 1977;2(6100):1457.
226. Jurgensen JC, Abraham JP, Hardy WW. Erythroid aplasia after halothane hepatitis. Report of a case. Am J Dig Dis 1970;15(6):577-581.
227. Geary CG. Drug-related red-cell aplasia. Br Med J 1978;1(6104):51-52.
228. Mariette X, Mitjavila MT, Moulinie JP, et al. Rifampicin-induced pure red cell aplasia. Am J Med 1989;87(4):459-460.
229. Giannone L, Kugler JW, Krantz SB. Pure red cell aplasia associated with administration of sustained-release procainamide. Arch Intern Med 1987;147(6):1179-1180.
230. Hoffman R, McPhedran P, Benz EJ Jr, et al. Isoniazid-induced pure red cell aplasia. Am J Med Sci 1983;286(1):2-9.
231. Dessypris EN. The biology of pure red cell aplasia. Semin Hematol 1991;28(4):275-284.
232. Chim CS, Ma SK. Giant pronormoblasts in parvovirus-associated pure red cell aplasia. Am J Hematol 2000;65(4):289.
233. Au WY, Cheng VC, Wan TS, et al. Myelodysplasia masquerading as parvovirus-related red cell aplasia with giant pronormoblasts. Ann Hematol 2004;83(10):670-671.
234. Kho L-K. Erythroblastopenia with giant pro-erythroblasts in kwashiorkor. Blood 1957;12(2):171-182.
235. Wibulyachainunt S, Price R, Brill AB, et al. Studies on red-cell aplasia: IX. Ferrokinetics during remission of the disease. Am J Hematol 1978;4(3): 233-244.
236. Keefer MJ, Solanki DL. Dyserythropoiesis and erythroblast-phagocytosis preceding pure red cell aplasia. Am J Hematol 1988;27(2):132-135.
237. Inui Y, Yamamoto K, Okamura A, et al. Isolated isochromosome 17q in myelodysplastic syndromes with pure red cell aplasia and basophilia. Intern Med 2012;51(12):1579-1584.
238. Garcia-Suarez J, Pascual T, Munoz MA, et al. Myelodysplastic syndrome with erythroid hypoplasia/aplasia: a case report and review of the literature. Am J Hematol 1998;58(4):319-325.
239. Lacy MQ, Kurtin PJ, Tefferi A. Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. Blood 1996;87(7):3000-3006.
240. Beard ME, Krantz SB, Johnson SA, et al. Pure red cell aplasia. Q J Med 1978;47(187):339-348.
241. Holborow EJ, Asherson GL, Johnson GD, et al. Antinuclear factor and other antibodies in blood and liver diseases. Br Med J 1963;1(5331):656-658.
242. Bai LY, Liu JH, Kau JP. T-cell clonal disorder in acquired primary pure red cell aplasia. Ann Hematol 2004;83(8):544-546.
243. Froland SS, Wisloff F, Stavem P. Abnormal lymphocyte populations in pure red cell aplasia. Scand J Haematol 1976;17(4):241-250.
244. Frickhofen N, Young NS. Polymerase chain reaction for detection of parvovirus B19 in immunodeficient patients with anemia. Behring Inst Mitt 1990(85): 46-54.
245. Frickhofen N, Abkowitz JL, Safford M, et al. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med 1990;113(12):926-933.
246. Clark DA, Dessypris EN, Krantz SB. Studies on pure red cell aplasia.XI. Results of immunosuppressive therapy of 37 patients. Blood 1984;63: 277-286.
247. Sawada K, Fujishima N, Hirokawa M. Acquired pure red cell aplasia: updated review of treatment. Br J Haematol 2008;142(4):505-514.
248. Sawada K, Hirokawa M, Fujishima N, et al. Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A, a nationwide cohort study in Japan for the PRCA Collaborative Study Group. Haematologica 2007;92(8):1021-1028.
249. Zaentz SD, Krantz SB, Brown EB. Studies on pure red cell aplasia. Maintenance therapy with immunosuppressive drugs. Br J Haematol 1976;32(1):47-54.
250. Finkel HE, Kimber RJ, Dameshek W. Corticosteroid-responsive acquired pure red cell aplasia in adults. Am J Med 1967;43(5):771-776.
251. Williams DL, Mageed AS, Findley H, et al. Cyclosporine in the treatment of red cell aplasia. Am J Pediatr Hematol Oncol 1987;9(4):314-316.
252. Totterman TH, Nisell J, Killander A, et al. Successful treatment of pure red-cell aplasia with cyclosporin. Lancet 1984;2(8404):693.
253. Auner HW, Wolfer A, Beham-Schmid C, et al. Restoration of erythopoiesis by rituximab in an adult patient with primary acquired pure red cell aplasia refractory to conventional treatment. Br J Haematol 2002;116:727-728.
254. Behler CM, Terrault NA, Etzell JE, et al. Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report. J Med Case Rep 2009;3:7335.
255. Mandreoli M, Finelli C, Lopez A, et al. Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia. Am J Kidney Dis 2004;44(4):757-761.
256. Zecca M, De SP, Nobili B, et al. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood 2001;97(12):3995-3997.
257. Jung SH, Ahn JS, Yang DH, et al. Successful treatment of pure red cell aplasia with rituximab in patients after ABO-compatible allogeneic hematopoietic stem cell transplantation. Case Rep Oncol 2012;5(1):110-113.
258. Park JH, Spitzer T, Kuter DJ. Successful treatment of pure red cell aplasia with autologous stem cell transplantation. Am J Hematol 2007;82(9): 812-814.
259. Verholen F, Stalder M, Helg C, et al. Resistant pure red cell aplasia after allogeneic stem cell transplantation with major ABO mismatch treated by escalating dose donor leukocyte infusion. Eur J Haematol 2004;73(6):441-446.
260. Woo HY, Min CK, Lee SM, et al. Resistant pure red cell aplasia after allogeneic bone marrow transplantation with major ABO mismatch treated by purified CD34+ cell infusion. Eur J Haematol 2006;76(2):160-163.
261. Dungarwalla M, Marsh JC, Tooze JA, et al. Lack of clinical efficacy of rituximab in the treatment of autoimmune neutropenia and pure red cell aplasia: implications for their pathophysiology. Ann Hematol 2007;86(3):191-197.
262. Antonio MR, Carmine S, Bianca S, et al. Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. Br J Haematol 2009;9999(9999).
263. Au WY, Lam CC, Chim CS, et al. Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia. Leuk Res 2005;29(10):1213-1215.
264. Schutzinger C, Gaiger A, Thalhammer R, et al. Remission of pure red cell aplasia in T-cell receptor gammadelta-large granular lymphocyte leukemia after therapy with low-dose alemtuzumab. Leukemia 2005;19(11):2005-2008.
265. Clauvel JP, Vainchenker W, Herrera A, et al. Treatment of pure red cell aplasia by high dose intravenous immunoglobulins. Br J Haematol 1983;55(2): 380-382.
266. Katakkar SB. Pure red blood cell aplasia: response to intravenous immunoglobulins, a blocking antibody. Arch Intern Med 1986;146(11):2288.
267. McGuire WA, Yang HH, Bruno E, et al. Treatment of antibody-mediated pure red-cell aplasia with high-dose intravenous gamma globulin. N Engl J Med 1987;317(16):1004-1008.
268. Mouthon L, Guillevin L, Tellier Z. Intravenous immunoglobulins in autoimmune- or parvovirus B19-mediated pure red-cell aplasia. Autoimmun Rev 2005;4(5):264-269.
269. Bavaro P, Di Girolamo G, Olioso P, et al. Donor lymphocyte infusion as therapy for pure red cell aplasia following bone marrow transplantation. Br J Haematol 1999;104(4):930-931.
270. Musso M, Porretto F, Crescimanno A, et al. Donor lymphocyte infusions for refractory pure red cell aplasia relapsing after both autologous and nonmyeloablative allogeneic peripheral stem cell transplantation. Bone Marrow Transplant 2004;33(7):769-771.
271. Messner HA, Fauser AA, Curtis JE, et al. Control of antibody-mediated pure red-cell aplasia by plasmapheresis. N Engl J Med 1981;304(22):1334-1338.
272. Ohta S, Yokoyama H, Ise T, et al. Apheresis therapy for prolonged red cell aplasia after major ABO-mismatched bone marrow transplantation. Intern Med 1997;36(7):487-491.
273. Or R, Naparstek E, Mani N, et al. Treatment of pure red-cell aplasia following major ABO-mismatched T-cell-depleted bone marrow transplantation. Two case reports with successful response to plasmapheresis. Transpl Int 1991;4(2): 99-102.
274. Freund LG, Hippe E, Strandgaard S, et al. Complete remission in pure red cell aplasia after plasmapheresis. Scand J Haematol 1985;35(3):315-318.
275. Abkowitz JL, Powell JS, Nakamura JM, et al. Pure red cell aplasia: response to therapy with anti-thymocyte globulin. Am J Hematol 1986;23(4): 363-371.
276. Zaentz DS, Krantz SB, Sears DA. Studies on pure red cell aplasia. VII. Presence of proerythroblasts and response to splenectomy: a case report. Blood 1975;46(2):261-270.
277. Kurstjens R, Haanen C. Remission of pure red cell aplasia obtained by splenectomy after failure of thymomectomy and immunosuppressive treatment. Ned Tijdschr Geneeskd 1978;122(33):1221-1225.
278. Sawada K, Koyanagawa Y, Deno M, et al. A case of pure red cell aplasia of which remission was obtained by splenectomy alone (author's transl.). Rinsho Ketsueki 1981;22(12):1955-1961.
279. Yamaguchi H, Muto K, Kamihira S, et al. A case of pure red cell aplasia with excellent response to splenectomy (author's transl.). Rinsho Ketsueki 1976;17(5):562-568.
280. Muller BU, Tichelli A, Passweg JR, et al. Successful treatment of refractory acquired pure red cell aplasia (PRCA) by allogeneic bone marrow transplantation. Bone Marrow Transplant 1999;23(11):1205-1207.
281. Kochethu G, Baden HS, Jaworska E, et al. Reduced intensity conditioning bone marrow transplantation for pure red cell aplasia: successful outcome but difficult post transplant course. Bone Marrow Transplant 2005;36(1): 81-82.
282. Subtirelu MM, Flynn JT, Schechner RS, et al. Acute renal failure in a pediatric kidney allograft recipient treated with intravenous immunoglobulin for parvovirus B19 induced pure red cell aplasia. Pediatr Transplant 2005;9(6):801-804.
283. Koduri PR, Kumapley R, Valladares J, et al. Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: use of intravenous immunoglobulin-a report of eight patients. Am J Hematol 1999;61(1):16-20.
284. Jiang D, Wu M. Thymectomy resulted in complete remission of pure red cell aplasia when associated with thymoma. Thorac Cardiovasc Surg 2010;58(4):235-236.
285. Krantz SB. Thymoma and red-cell aplasia. N Engl J Med 1973;288(22): 1185-1186.
286. Peschle C, Condorelli M. Pure red cell aplasia associated with thymoma. Demonstration of an autoimmune serum factor inhibiting erythropoiesis and remission induced by cyclophosphamide. Haematologica 1972;58(9): 553-559.
287. Thompson CA, Steensma DP. Pure red cell aplasia associated with thymoma: clinical insights from a 50-year single-institution experience. Br J Haematol 2006;135(3):405-407.
288. van der Marel J, Pahlplatz PV, Steup WH, et al. Thymoma with paraneoplastic syndromes, Good's syndrome, and pure red cell aplasia. J Thorac Oncol 2007;2(4):325-326.
289. Yoshida S, Konishi T, Nishizawa T, et al. Effect of tacrolimus in a patient with pure red-cell aplasia. Clin Lab Haematol 2005;27(1):67-69.
290. Zaucha R, Zaucha JM, Jassem J. Resolution of thymoma-related pure red cell aplasia after octreotide treatment. Acta Oncol 2007;46(6):864-865.
291. Carson KR, Evens AM, Bennett CL, et al. Clinical characteristics of erythropoietin-associated pure red cell aplasia. Best Pract Res Clin Haematol 2005;18(3):467-472.
292. Casadevall N. Epoetin-induced autoimmune pure red cell aplasia. Hematol J 2004;5(Suppl 3):S104- S109.
293. Duffield JS, Mann S, Horn L, et al. Low-dose cyclosporin therapy for recombinant erythropoietin-induced pure red-cell aplasia. Nephrol Dial Transplant 2004;19(2):479-481.
294. Fraer M, Campbell A, Sawaya BP. Response to cyclosporine A in a patient with pure red cell aplasia due to antierythropoietin-alpha antibodies. Semin Dial 2006;19(3):251-254.
295. Shinohara K. Pure red cell aplasia caused by antibody to erythropoietin successfully treated by cyclosporine administration. Am J Hematol 2007;82(3): 247-248.
296. Westerlund P, Kurkus J, Segelmark M. Rapid resolution of EPO-induced pure red cell aplasia after a course of immunoadsorption therapy using protein A columns. Am J Kidney Dis 2005;45(6):e97- e99.
297. Katagiri D, Shibata M, Katsuki T, et al. Antiepoetin antibody-related pure red cell aplasia: successful remission with cessation of recombinant erythropoietin alone. Clin Exp Nephrol 2010;14(5):501-505.
298. Andrade J, Taylor PA, Love JM, et al. Successful reintroduction of a different erythropoiesis-stimulating agent after pure red cell aplasia: relapse after successful therapy with prednisone. Nephrol Dial Transplant 2005;20(11): 2548-2551.
299. Asari A, Gokal R. Pure red cell aplasia secondary to epoetin alpha responding to darbepoetin alpha in a patient on peritoneal dialysis. J Am Soc Nephrol 2004;15(8):2204-2207.
300. Lee H, Yang J, Kim H, et al. Improvement in erythropoieis-stimulating agentinduced pure red-cell aplasia by introduction of darbepoetin-alpha when the anti-erythropoietin antibody titer declines spontaneously. J Korean Med Sci 2010;25(11):1676-1679.
301. Summers SA, Matijevic A, Almond MK, Successful re-introduction of recombinant human erythropoietin following antibody induced pure red cell aplasia. Nephrol Dial Transplant 2004;19(8):2137-2139.
302. Vartia A, Asola MR, Tertti R, et al. Two haemodialysis patients with epoetin alfa-induced pure red-cell aplasia recovered despite treatment with another epoetin preparation. Nephrol Dial Transplant 2004;19(5):1313-1316.
303. Summers S, Holdsworth S, Sharples E. The (re)challenging question of erythropoiesis-stimulating agents inducing pure red cell aplasia. Nephrol Dial Transplant 2008;23(10):3053-3055.
304. Praditpornsilpa K, Tiranathagul K, Kupatawintu P. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int 2011;80:88-92.
305. Macdougall IC, Rossert J, Casadevall N, et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N.Engl.J.Med 2009;361(19): 1848-1855.
306. Baer AN, Dessypris EN, Goldwasser E, et al. Blunted erythropoietin response to anaemia in rheumatoid arthritis. Br J Haematol 1987;66:559-564.
307. McMahon JN, Egan EL. Aplastic anaemia in a patient with pure red cell aplasia. Ir J Med Sci 1980;149(5):212-214.
308. Diamond LK, Blackfan KD. Hypoplastic anemia. Am J Dis Child 1938;56:464.
309. Young NS, Alter BP. Aplastic anemia acquired and inherited. Philadelphia: WB Saunders Co, 1994.
310. Diamond LK, Wang WC, Alter BP. Congenital hypoplastic anemia. Adv Pediatr 1976;22:349-378.
311. Vlachos A, Ball S, Dahl N, et al. Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference. Br J Haematol 2008;142(6):859-876.
312. Vlachos A, Klein GW, Lipton JM. The Diamond Blackfan Anemia Registry: tool for investigating the epidemiology and biology of Diamond-Blackfan anemia. J Pediatr Hematol Oncol 2001;23(6):377-382.
313. Ortega JA, Shore NA, Dukes PP, et al. Congenital hypoplastic anemia inhibition of erythropoiesis by sera from patients with congenital hypoplastic anemia. Blood 1975;45(1):83-89.
314. Hoffman R, Zanjani ED, Vila J, et al. Diamond-Blackfan syndrome: lymphocyte-mediated suppression of erythropoiesis. Science 1976;193(4256): 899-900.
315. Sawada K, Koyanagawa Y, Sakurama S, et al. Diamond-Blackfan syndrome: a possible role of cellular factors for erythropoietic suppression. Scand J Haematol 1985;35(2):158-165.
316. Ershler WB, Ross J, Finlay JL, et al. Bone-marrow microenvironment defect in congenital hypoplastic anemia. N Engl J Med 1980;302(24):1321-1327.
317. Finlay JL, Shahidi NT, Horowitz S, et al. Lymphocyte dysfunction in congenital hypoplastic anemia. J Clin Invest 1982;70(3):619-626.
318. Nathan DG, Clarke BJ, Hillman DG, et al. Erythroid precursors in congenital hypoplastic (Diamond-Blackfan) anemia. J Clin Invest 1978;61(2):489-498.
319. Lipton JM, Kudisch M, Gross R, et al. Defective erythroid progenitor differentiation system in congenital hypoplastic (Diamond-Blackfan) anemia. Blood 1986;67(4):962-968.
320. Tsai PH, Arkin S, Lipton JM. An intrinsic progenitor defect in Diamond-Blackfan anaemia. Br J Haematol 1989;73(1):112-120.
321. Perdahl EB,Naprstek BL,WallaceWC,et al. Erythroid failure in Diamond-Blackfan anemia is characterized by apoptosis. Blood 1994;83(3):645-650.
322. Ohene-Abuakwa Y, Orfali KA, Marius C, et al. Two-phase culture in Diamond Blackfan anemia: localization of erythroid defect. Blood 2005;105(2): 838-846.
323. Lipton JM, Ellis SR. Diamond Blackfan anemia 2008-2009: broadening the scope of ribosome biogenesis disorders. Curr Opin Pediatr 2010;22(1):12-19.
324. Farrar JE, Vlachos A, Atsidaftos E, et al. Ribosomal protein gene deletions in Diamond-Blackfan anemia. Blood 2011;118(26):6943-6951.
325. Sankaran VG, Ghazvinian R, Do R, et al. Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia. J Clin Invest 2012;122(7):2439-2443.
326. Lipton JM, Nathan DG. Cell-cell interactions in the regulation of erythropoiesis. Br J Haematol 1983;53(3):361-367.
327. Geller G, Drivit W, Zalusky R, et al. Lack of erythropoietic inhibitory effect of serum from patients with congenital pure red cell aplasia. N Engl J Med 1975;292(9):198-201.
328. Freedman MH, Saunders EF. Diamond-Blackfan syndrome: evidence against cell-mediated erythropoietic suppression. Blood 1978;51(6):1125-1128.
329. Nathan DG, Hillman DG, Chess L, et al. Normal erythropoietic helper T cells in congenital hypoplastic (Diamond-Blackfan) anemia. N Engl J Med 1978;298(19):1049-1051.
330. Chan HS, Saunders EF, Freedman MH. Diamond-Blackfan syndrome. I. Erythropoiesis in prednisone responsive and resistant disease. Pediatr Res 1982;16(6):474-476.
331. Chan HS, Saunders EF, Freedman MH. Diamond-Blackfan syndrome. II. In vitro corticosteroid effect on erythropoiesis. Pediatr Res 1982;16(6):477-478.
332. McGuckin CP, Ball SE, Gordon-Smith EC. Diamond-Blackfan anaemia: three patterns of in vitro response to haemopoietic growth factors. Br J Haematol 1995;89(3):457-464.
333. Varricchio L, Godbold J, Scott SA, et al. Increased frequency of the glucocorticoid receptor A3669G (rs6198) polymorphism in patients with Diamond-Blackfan anemia. Blood 2011;118(2):473-474.
334. Dianzani I, Garelli E, Dompe C, et al. Mutations in the erythropoietin receptor gene are not a common cause of Diamond-Blackfan anemia. Blood 1996;87(6):2568-2572.
335. Bagnara GP, Zauli G, Vitale L, et al. In vitro growth and regulation of bone marrow enriched CD34+ hematopoietic progenitors in Diamond-Blackfan anemia. Blood 1991;78(9):2203-2210.
336. Giri N, Kang E, Tisdale JF, et al. Clinical and laboratory evidence for a trilineage haematopoietic defect in patients with refractory Diamond-Blackfan anaemia. Br J Haematol 2000;108(1):167-175.
337. van Diemen PC, Maasdam D, Darroudi F, et al. X-ray-sensitivity of lymphocytes of aplastic- and Diamond-Blackfan-anemia patients as detected by conventional cytogenetic and chromosome painting techniques. Mutat Res 1997;373(2): 225-235.
338. Abkowitz JL, Sabo KM, Nakamoto B, et al. Diamond-Blackfan anemia: in vitro response of erythroid progenitors to the ligand for c-kit. Blood 1991;78(9):2198-2202.
339. Sieff CA, Yokoyama CT, Zsebo KM, et al. The production of steel factor mRNA in Diamond-Blackfan anaemia long-term cultures and interactions of steel factor with erythropoietin and interleukin-3. Br J Haematol 1992;82(4): 640-647.
340. Spritz RA, Freedman MH. Lack of mutations of the MGF and KIT genes in Diamond-Blackfan anemia. Blood 1993;81(11):3165.
341. Scopes J, Daly S, Ball SE, et al. The effect of human flt-3 ligand on committed progenitor cell production from normal, aplastic anaemia and Diamond-Blackfan anaemia bone marrow. Br J Haematol 1995;91(3):544-550.
342. McGuckin CP, Uhr MR, Liu WM, et al. The use of recombinant SCF protein for rapid determination of c-kit expression in normal and abnormal erythropoiesis. Eur J Haematol 1996;57(1):72-78.
343. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008;451(7176):335-339.
344. Vlachos A, Farrar J, Atsidaftos E, et al. 5q-myelodysplastic syndrome, in Diamond Blackfan Anemia (DBA) and responding to lenalidomide. Blood 2010;16. Late Breaking Abstract Session.
345. Gustavsson P, Willing TN, van Haeringen A, et al. Diamond-Blackfan anaemia: genetic homogeneity for a gene on chromosome 19q13 restricted to 1.8 Mb. Nat Genet 1997;16(4):368-371.
346. Draptchinskaia N, Gustavsson P, Andersson B, et al. The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nat Genet 1999;21(2):169-175.
347. Gazda HT, Grabowska A, Merida-Long LB, et al. Ribosomal protein S24 gene is mutated in Diamond-Blackfan anemia. Am J Hum Genet 2006;79(6): 1110-1118.
348. Kuramitsu M, Sato-Otsubo A, Morio T, et al. Extensive gene deletions in Japanese patients with Diamond-Blackfan anemia. Blood 2012;119(10): 2376-2384.
349. Cmejla R, Cmejlova J, Handrkova H, et al. Ribosomal protein S17 gene (RPS17) is mutated in Diamond-Blackfan anemia. Hum Mutat 2007;28(12): 1178-1182.
350. Farrar JE, Nater M, Caywood E, et al. Abnormalities of the large ribosomal subunit protein, Rpl35a, in Diamond-Blackfan anemia. Blood 2008;112(5):1582-1592.
351. Gazda HT, Sheen MR, Vlachos A, et al. Ribosomal protein L5 and L11 mutations are associated with cleft palate and abnormal thumbs in Diamond-Blackfan anemia patients. Am J Hum Genet 2008;83(6):769-780.
352. Gazda HT, Sheen M, Doherty L, et al. Ribosomal protein genes S10 and S26 are commonly mutated in Diamond-Blackfan anemia. Blood 2010;114:175.
353. Doherty L, Sheen MR, Vlachos A, et al. Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan anemia. Am J Hum Genet 2010;86(2):222-228.
354. Gazda HT, Landowski M, Buros C, et al. Array comparative hybridization of ribosomal protein genes in Diamond-Blackfan anemia patients RPS8, RPS14 and RPL15 with large deletion of duplication (abstract). Blood 2010;116:1007.
355. Gazda HT, Zhong R, Long L, et al. RNA and protein evidence for haplo-insufficiency in Diamond-Blackfan anaemia patients with RPS19 mutations. Br J Haematol 2004;127(1):105-113.
356. Flygare J, Kiefer T, Miyake K, et al. Deficiency of ribosomal protein S19 in CD34+ cells generated by siRNA blocks erythroid development and mimics defects seen in Diamond-Blackfan anemia. Blood 2005;105(12):4627-4634.
357. Ebert BL, Lee MM, Pretz JL, et al. An RNA interference model of RPS19 deficiency in Diamond-Blackfan anemia recapitulates defective hematopoiesis and rescue by dexamethasone: identification of dexamethasone-responsive genes by microarray. Blood 2005;105(12):4620-4626.
358. Hamaguchi I, Ooka A, Brun A, Richter J, Dahl N, Karlsson S. Gene transfer improves erythroid development in ribosomal protein S-19 deficient Diamond-Blackfan anemia. Blood 2005;100:2724-2731.
359. Devlin EE, Dacosta L, Mohandas N, et al. A transgenic mouse model demonstrates a dominant negative effect of a point mutation in the RPS19 gene associated with Diamond-Blackfan anemia. Blood 2010;116(15): 2826-2835.
360. McGowan KA, Li JZ, Park CY, et al. Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects. Nat Genet 2008;40(8):963-970.
361. Danilova N, Sakamoto KM, Lin S. Ribosomal protein S19 deficiency in zebrafish leads to developmental abnormalities and defective erythropoiesis through activation of p53 protein family. Blood 2008;112(13):5228-5237.
362. Uechi T, Nakajima Y, Chakraborty A, et al. Deficiency of ribosomal protein S19 during early embryogenesis leads to reduction of erythrocytes in a zebrafish model of Diamond-Blackfan anemia. Hum Mol Genet 2008;17(20):3204-3211.
363. Lipton JM, Federman N, Khabbaze Y, et al. Osteogenic sarcoma associated with Diamond-Blackfan anemia: a report from the Diamond-Blackfan Anemia Registry. J Pediatr Hematol Oncol 2001;23(1):39-44.
364. Vlachos A, Rosenberg PS, Atsidaftos E, et al. Incidence of neoplasia in Diamond Blackfan anemia: a report from the Diamond Blackfan Anemia Registry. Blood 2012;119(16):3815-3819.
365. Fumagalli S, Thomas G. The role of p53 in ribosomopathies. Semin Hematol 2011;48(2):97-105.
366. Horos R, Ijspeert H, Pospisilova D, et al. Ribosomal deficiencies in Diamond-Blackfan anemia impair translation of transcripts essential for differentiation of murine and human erythroblasts. Blood 2012;119(1): 262-272.
367. Xue S, Barna M. Specialized ribosomes: a new frontier in gene regulation and organismal biology. Nature reviews. Mol Cell Biol 2012;13(6):355-369.
368. McGowan KA, Mason PJ. Animal models of Diamond Blackfan anemia. Semin Hematol 2011;48(2):106-116.
369. Scimeca PG, Weinblatt ME, Slepowitz G, et al. Diamond-Blackfan syndrome: an unusual cause of hydrops fetalis. Am J Pediatr Hematol Oncol 1988;10(3): 241-243.
370. Balaban EP, Buchanan GR, Graham M, et al. Diamond-Blackfan syndrome in adult patients. Am J Med 1985;78(3):533-538.
371. Josephs H. Anemia of infancy and early childhood. Medicine 1936;15:307.
372. Alter BP. Modern review of congenital hypoplastic anemia. J Pediatr Hematol Oncol 2001;23(6):383-384.
373. Lipton JM, Atsidaftos E, Zyskind I, et al. Improving clinical care and elucidating the pathophysiology of Diamond Blackfan anemia: an update from the Diamond Blackfan Anemia Registry. Pediatr Blood Cancer 2006;46(5):558-564.
374. Vlachos A, Federman N, Reyes-Haley C, et al. Hematopoietic stem cell transplantation for Diamond Blackfan anemia: a report from the Diamond Blackfan Anemia Registry. Bone Marrow Transplant 2001;27(4):381-386.
375. Alter BP. The bone marrow failure syndromes. In: Nathan DG, ed. Hematology of infancy and childhood, 3rd ed. Philadelphia: W.B. Saunders, 1987:159-241.
376. Aase JM, Smith DW. Congenital anemia and triphalangeal thumbs: a new syndrome. J Pediatr 1969;74(3):471-474.
377. Schroeder WA, Huisman THJ, Brown AD, et al. Postnatal changes in the chemical heterogeneity of human fetal hemoglobin. Pediatr Res 1971;9:493.
378. Alter BP. Childhood red cell aplasia. Am J Pediatr Hematol Oncol 1980;2:121.
379. Buchanan GR, Alter BP, Holtkamp CA, et al. Platelet number and function in Diamond-Blackfan anemia. Pediatrics 1981;68(2):238-241.
380. Glader BE, Backer K. Comparative activity of erythrocyte adenosine deaminase and orotidine decarboxylase in Diamond-Blackfan anemia. Am J Hematol 1986;23(2):135-139.
381. Glader BE, Backer K. Elevated red cell adenosine deaminase activity: a marker of disordered erythropoiesis in Diamond-Blackfan anaemia and other haematologic diseases. Br J Haematol 1988;68(2):165-168.
382. Glader BE, Backer K, Diamond LK. Elevated erythrocyte adenosine deaminase activity in congenital hypoplastic anemia. N Engl J Med 1983;309(24): 1486-1490.
383. Zielke HR, Ozand PT, Luddy RE, et al. Elevation of pyrimidine enzyme activities in the RBC of patients with congenital hypoplastic anaemia and their parents. Br J Haematol 1979;42(3):381-390.
384. Harrison DE, Malathi VG, Silber R. Elevated erythrocyte nucleoside deaminase levels in genetically anemic W/Wv and Sl/Sld mice. Blood Cells 1975;1:605.
385. Brookfield EG, Singh P. Congenital hypoplastic anemia associated with hypogammaglobulinemia. J Pediatr 1974;85(4):529-531.
386. Khan S, Pereira J, Darbyshire PJ, et al. Do ribosomopathies explain some cases of common variable immunodeficiency? Clin Exp Immunol 2011;163(1):96-103.
387. Bernard J, Seligmann M, Chassigneux J, et al. Blackfan-Diamond anemia. Nouv Rev Fr Hematol 1962;2:721-739.
388. Gordon RR, Varadi S. Congenital hypoplastic anaemia (pure red-cell anaemia) with periodic erythroblastopenia. Lancet 1962;1:296-299.
389. Sensenbrenner J. Congenital hypoplastic anemia of Blackfan and Diamond in sibs. In: Bergsma D, ed. The clinical delineation of birth defects. Baltimore, MD: Williams and Wilkins, 1972.
390. Starling KA, Fernbach DJ. Hypoplastic anemia. J Pediatr 1973;82:735.
391. Waterkotte GW, McElfresh AE. Congenital pure red cell hypoplasis in identical twins. Pediatrics 1974;54(5):646-647.
392. Altman AC, Gross S. Severe congenital hypoplastic anemia. Transmission from a healthy female to opposite sex step-siblings. Am J Pediatr Hematol Oncol 1983;5(1):99-101.
393. Forare SA. Pure red cell anemia in step siblings. Acta Paediatr 1963;52: 159-160.
394. Hunter RE, Hakami N. The occurrence of congenital hypoplastic anemia in half brothers. J Pediatr 1972;81(2):346-348.
395. Mott MG, Apley J, Raper AB. Congenital (erythroid) hypoplastic anaemia: modified expression in males. Arch Dis Child 1969;44(238):757-760.
396. Hamilton PJ, Dawson AA, Galloway WH. Congenital erythroid hypoplastic anaemia in mother and daughter. Arch Dis Child 1974;49(1):71-73.
397. Lawton JW, Aldrich JE, Turner TL. Congenital erythroid hypoplastic anaemia: autosomal dominant transmission. Scand J Haematol 1974;13(4):276-280.
398. Michelson AD. Inheritance of Diamond-Blackfan anemia. Med J Aust 1982;2(9):409-410.
399. Gray PH. Pure red-cell aplasia. Occurrence in three generations. Med J Aust 1982;1(12):519-521.
400. Gustavsson P, Skeppner G, Johansson B, et al. Diamond-Blackfan anaemia in a girl with a de novo balanced reciprocal X;19 translocation. J Med Genet 1997;34(9):779-782.
401. Gripp KW, McDonald-McGinn DM, La Rossa D, et al. Bilateral microtia and cleft palate in cousins with Diamond-Blackfan anemia. Am J Med Genet 2001;101(3):268-274.
402. Orfali KA, Ohene-Abuakwa Y, Ball SE. Diamond Blackfan anaemia in the UK: clinical and genetic heterogeneity. Br J Haematol 2004;125(2):243-252.
403. Cmejla R, Blafkova J, Stopka T, et al. Ribosomal protein S19 gene mutations in patients with diamond-blackfan anemia and identification of ribosomal protein S19 pseudogenes. Blood Cells Mol Dis 2000;26(2):124-132.
404. Tada K, Kudo T, Nakagawa I, et al. [Not Available] [Article in French] Arch Fr Pediatr 1958;15(2):183-194.
405. Diamond LK, Allen DM, Magill FB. Congenital (erythroid) hypoplastic anemia. A 25-year study. Am J Dis Child 1961;102:403-415.
406. Orfali KA, Wynn RF, Stevens R, et al. Failure of red cell production following allogeneic BMT for Diamond-Blackfan anaemia (DBA) illustrates functional significance of high erythrocyte adenosine deaminase (eADA) activity in the donor. Blood 1999;94:414a.
407. Vlachos A, Dahl N, Dianzani I, et al. Clinical utility gene card for: Diamond Blackfan anemia. Eur J Hum Genet 2013 Mar 6 doi:10.1038/ejhg.2013.34 [E pub ahead of print].
408. Talerman A, Amigo A. Thymoma associated with aregenerative and aplastic anemia in a five-year-old child. Cancer 1968;21(6):1212-1218.
409. Young N, Mortimer P. Viruses and bone marrow failure. Blood 1984;63(4): 729-737.
410. Young NS, Mortimer PP, Moore JG, et al. Characterization of a virus that causes transient aplastic crisis. J Clin Invest 1984;73(1):224-230.
411. Kelleher JF, Luban NL, Mortimer PP, et al. Human serum "parvovirus": a specific cause of aplastic crisis in children with hereditary spherocytosis. J Pediatr 1983;102(5):720-722.
412. Van Horn DK, Mortimer PP, Young N, et al. Human parvovirus-associated red cell aplasia in the absence of underlying hemolytic anemia. Am J Pediatr Hematol Oncol 1986;8(3):235-239.
413. Wang WC, Mentzer WC. Differentiation of transient erythroblastopenia of childhood from congenital hypoplastic anemia. J Pediatr 1976;88(5):784-789.
414. Link MP, Alter BP. Fetal-like erythropoiesis during recovery from transient erythroblastopenia of childhood. Pediatr Res 1981;15:1036.
415. Gasser C. Aplastic anemia (chronic erythroblastophthisis) and cortisone. Schweiz Med Wochenschr 1951;81(50):1241-1242.
416. Hill JM, HR. ACTH therapy in refractory anemias. Proceedings of the Second Clinical ACTH Conference, New York, NY, 1987.
417. Ozsoylu S. High-dose intravenous corticosteroid treatment for patients with Diamond-Blackfan syndrome resistant or refractory to conventional treatment. Am J Pediatr Hematol Oncol 1988;10(3):217-223.
418. Ozsoylu S, Coskun T, Minassazi S. High dose intravenous glucocorticoid in the treatment of childhood acquired aplastic anaemia. Scand J Haematol 1984;33(3):309-316.
419. Buchanan GR. Oral megadose methylprednisolone therapy for refractory Diamond-Blackfan anemia. International Diamond-Blackfan Anemia Study Group. J Pediatr Hematol Oncol 2001;23(6):353-356.
420. August CS, King E, Githens JH, et al. Establishment of erythropoiesis following bone marrow transplantation in a patient with congenital hypoplastic anemia (Diamond-Blackfan syndrome). Blood 1976;48(4):491-498.
421. Alter BP. Bone marrow transplant in Diamond-Blackfan anemia. Bone Marrow Transplant 1998;21(9):965-966.
422. Aghalar J, Atsidaftos E, Lipton JM, Vlachos A. Improved outcomes in Diamond Blackfan anemia treated via stem cell transplantation since the year 2000. ASH Annu Meeting Abstr 2009;114:3202.
423. Willig TN, Niemeyer CM, Leblanc T, et al. Identification of new prognosis factors from the clinical and epidemiologic analysis of a registry of 229 Diamond-Blackfan anemia patients. DBA group of Société d'Hématologie et d'Immunologie Pédiatrique (SHIP), Gesellshaft für Pädiatrische Onkologie und Hämatologie (GPOH), and the European Society for Pediatric Hematology and Immunology (ESPHI). Pediatr Res 1999;46(5):553-561.
424. Vlachos A, Muir E. How I treat Diamond-Blackfan anemia. Blood 2010; 116(19):3715-3723.
425. Lipton JM, de Alarcon PA, Louis K. Diamond: an incomparable legacy. J Pediatr Hematol/Oncol 2001;23(6):371-372.